Physician profile
Samantha M Shenoy
NPI 1083959811
$30,929.43
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $125 · 2023: $1,787 · 2024: $10K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $7,404 · Grant: $2,171 · Food and Beverage: $1,797 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,185 · Honoraria: $990 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,595.25 |
| Travel and Lodging | $7,403.62 |
| Grant | $2,171.39 |
| Food and Beverage | $1,796.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,185.00 |
| Honoraria | $990.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $425.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11,191.27 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Janssen Global Services, LLC | $11,169.05 | 2021-2025 | Carvykti |
| Janssen Scientific Affairs, LLC | $3,690.84 | 2023-2024 | Darzalex, Talvey, Tecvayli |
| Genzyme Corporation | $2,171.39 | 2025 | |
| Pfizer INC. | $810.00 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $524.00 | 2025 | Lynozyfic |
| Taiho Oncology, INC. | $382.14 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $251.51 | 2025 | |
| Legend Biotech USA INC. | $229.71 | 2025 | Carvykti |
| Abbvie INC. | $187.06 | 2022-2025 | |
| Janssen Research & Development, LLC | $107.71 | 2024 | Talvey |
| Beigene USA, INC. | $97.20 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $58.38 | 2023 | Imbruvica, Epkinly |
| Genmab U.S., INC. | $22.36 | 2024 | Epkinly |
| Genentech USA, INC. | $20.21 | 2023 | Columvi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $16.60 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Shenoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.